About the Company
Ariosa Diagnostics, Inc., is a molecular diagnostics company committed to innovating together to improve patient care. The flagship product, the Harmony Prenatal Test, is a safe, highly accurate and affordable prenatal test for maternal and fetal health. Led by an experienced team, Ariosa is using its proprietary technology to perform a directed analysis of cell-free DNA in blood. The Harmony test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety.
The company was incorporated in 2008 and is headquartered in San Jose, Calif. For more information, visit www.ariosadx.com.
John Stuelpnagel, DVM
John Stuelpnagel has been Executive Chairman of Ariosa Diagnostics since 2009. Prior to Ariosa, John co-founded Illumina, Inc. and during his 12 years at Illumina, he served as the company's first CEO and most recently served as COO. Prior to Illumina, John was a venture capitalist at CW Group. John received his B.S. in Biochemistry and his Doctorate in Veterinary Medicine from the University of California, Davis and his M.B.A. from the University of California, Los Angeles.
Ken Song, MD
Chief Executive Officer
Ken Song brought together the initial team for Ariosa Diagnostics and has served as CEO since 2009. Prior to Ariosa, Ken was an investor at Venrock and led multiple investments in healthcare companies. Ken is a board certified physician, has extensive clinical and basic science research experience, and was previously a consultant at McKinsey & Company. Ken received his B.S. in Biology from the Massachusetts Institute of Technology and his M.D. from the University of California, San Francisco.
President & Chief Operating Officer
Dave Mullarkey oversees Ariosa's US and international commercial growth. He has over 25 years of healthcare experience. Prior to Ariosa, Dave led the growth of Valeant Pharmaceutical's dermatology business unit from $70 to $700M as Senior Vice President & General Manager. He started his career in sales with Eli Lilly and has managed businesses as well as led teams at companies such as Johnson & Johnson, Coopers & Lybrand Consulting, Dow Pharmaceutical Sciences and SCIREX (now Premier Research). Dave received his M.B.A. from the Kellogg School of Management at Northwestern University and B.S. from Cornell University.
Arnold Oliphant, PhD
Chief Scientific Officer
Arnold Oliphant has served as CSO of Ariosa Diagnostics since early 2010 and led development of the company's proprietary assay platform. Arnold has over 20 years of industry experience in developing and commercializing novel assays for research and clinical use. He has led multi-disciplinary research and development teams at Myriad Genetics, Illumina, and Complete Genomics. Arnold is an inventor on numerous patents and has co-authored several landmark papers in the field of human genetics. Arnold received his B.A. in Genetics from the University of Utah and his Ph.D. in Genetics from Harvard University.
Thomas Musci, MD
Chief Medical Officer
Thomas Musci oversees all efforts related to clinical trials and medical education for the Harmony test as well as other products in development. Recognized as a leader in clinical research on prenatal testing, Dr. Musci has served as chair of the Genetics Committee for the American Congress of Obstetricians and Gynecologists (ACOG), and he is currently a member of the Professional Practice Guidelines Committee for the American College of Medical Genetics (ACMG). He was co-founder of San Francisco Perinatal Associates, Inc., and retains an appointment as associate clinical professor with the Department of Obstetrics and Gynecology at University of California, San Francisco (UCSF).
Dan Puckett, MBA
Chief Financial Officer
Dan Puckett joined Ariosa in 2011 and is responsible for leading the finance and human resources functions. Dan came to Ariosa from Forest Laboratories where he served as Executive Director, Operations of Cerexa, a Forest Laboratories subsidiary. While at Cerexa, Dan was part of the leadership team that was responsible for obtaining FDA approval for the drug Teflaro. Prior to Cerexa, Dan held senior finance and operations positions at Affymetrix, AOL, Viad, and BHP Billiton. Dan holds an M.B.A. from the University of San Francisco and a B.A. degree in accounting from Washington State University.
Andrew Sparks, PhD
Senior Vice President, Development and Operations
Andrew Sparks joined Ariosa Diagnostics in 2010. Andrew is responsible for leading Ariosa's clinical lab operations, having successfully spearheaded development of Ariosa's assay platform. Andrew has over 15 years' experience developing and deploying large-scale genetic analysis technologies. Prior to joining Ariosa, Andrew led R&D and lab operation teams at Complete Genomics, Perlegen, and Affymetrix. Andrew has authored over 25 scientific publications, and is an inventor on over 15 patents. Andrew received his B.S. in Biology from the University of Texas, his Ph.D. in Genetics from the University of North Carolina, and was a postdoctoral fellow at Johns Hopkins University.
Dianna DeVore, PhD, JD
Senior Vice President, Intellectual Property and Legal Affairs
Dianna DeVore has led the IP and legal affairs of Ariosa Diagnostics since Fall 2010. Dianna has over 16 years of legal experience, with a focus on intellectual property and technology transactions. She was a founder of the Silicon Valley-based law firm, Convergent Law Group, and served as legal counsel at numerous companies, including Complete Genomics, Cambridge Antibody Technology and Elan Pharmaceuticals. Dianna received her B.A in Biology and Art History from Johns Hopkins, her Ph.D. in Genetics from Yale University, and her J.D. from Stanford Law School.
Vice President, Informatics
Todd Rubano assumed responsibility in 2011 for automating the cutting-edge tests developed by the scientific team at Ariosa Diagnostics. Todd also leads teams in laboratory information systems, business applications and other information technology. Prior to joining Ariosa, Todd directed the Laboratory Automation & Systems Integration group at Illumina, Inc. He joined Illumina from Myriad Genetics where he led the engineering effort to automate the first commercially available DNA sequence-based test for breast cancer. Todd received his B.S. in Systems Engineering from University of Arizona and his M.E. in Engineering Systems from Colorado School of Mines.
Vice President, Sales and Commercial Operations
Todd Whitson joined Ariosa Diagnostics in 2011 as the first commercial hire of the organization. He is responsible for building the commercial team with an emphasis on sales and operations. Todd has held various sales leadership roles in healthcare over the last 10 years with increasing responsibility, most recently leading the integration of the combined oncology sales force for Genzyme Genetics and LabCorp. Prior to that, Todd led sales related activities at Genzyme Genetics for reproductive and oncology diagnostic products. Todd received his BA in Business/Economics and Psychology from Lafayette College and a Masters in Sports Administration from Richmond College.
Vice President, Operations
Celeste McBride joined Ariosa in 2010. She has 20 years of experience in the industry developing, managing and implementing large scale genotyping and sequencing operations. Celeste led successful process development teams and managed service laboratory operations at Myriad Genetics, Illlumina and Complete Genomics. She began her career in the Pathology department at Baylor College of Medicine and received her BS in Biology from University of Houston.
Board of Directors
John Stuelpnagel, DVM
John Stuelpnagel has been Executive Chairman of Ariosa Diagnostics since 2009. Prior to Ariosa, John co-founded Illumina, Inc. and was instrumental in making Illumina one of the most successful life science companies. During his 12 years at Illumina, John served as the company’s first CEO and most recently served as COO. Prior to Illumina, John was a venture capitalist at CW Group. John received his B.S. in Biochemistry and his Doctorate in Veterinary Medicine from the University of California, Davis and his M.B.A. from the University of California, Los Angeles.
Kim Kamdar, PhD
Kim Kamdar is a Partner at Domain Associates. Prior to Domain, Kim was a Kauffman Fellow with MPM Capital from 2003-2004. Prior to joining MPM, Kim was a Research Director at Novartis. In addition to Ariosa, Kim serves on the board of Nuon Therapeutics, Obalon Therapeutics, ROX Medical, Sonexa Therapeutics, Syndax Pharmaceuticals, Tragara Pharmaceuticals, as well as observer status at Achaogen, BiPar Sciences, Corthera, GenVault, Lipothera and SkinMedica. Kim serves as an advisory board member to Eric Topol’s NIH supported Clinical and Translational Science Award for Scripps Medicine. Additionally, Kim serves as an Advisory Board Member for Evolvence India Life Sciences Fund, a private equity fund providing growth capital to Indian pharmaceutical and biotechnology companies.
Michael Aicher, MBA
Michael Aicher is co-founder and CEO of the National Genetics Institute (NGI), a wholly-owned subsidiary of Laboratory Corporation of America® Holdings (LabCorp®). In his over 20 years in molecular diagnostics, he has steered the implementation of an initial treatment model for HCV and secured the first FDA-approved HIV/HCV PCR tests for plasma donor screening, with 15 million donations per year tested. Under various leadership positions at LabCorp, he helped drive revenue and margins within the esoteric testing business. Recognition for Mr. Aicher includes distinction as an Ernst & Young "Entrepreneur of the Year" for Emerging Technologies. Mr. Aicher recently took on the CEO position at Omicia, a DNA sequencing informatics company.
Bryan Roberts, PhD
Bryan Roberts, Ph.D. joined Venrock as a Kauffman Fellow in 1997. He is based in Venrock's Palo Alto office and focuses on a broad range of healthcare investments. Bryan is currently Chairman of the Board of Directors of Achaogen, Castlight Health, and Ironwood Pharmaceuticals (NASDAQ: IRWD) and also serves on the Board of several other private companies, including Ariosa Diagnostics, Ikaria, Intarcia, and Kyruus. Bryan was named a Henry Crown Fellow by the Aspen Institute in 2006 and has been the highest-ranking healthcare investor on Forbes' Midas List since 2008. Bryan received his Ph.D. in Chemistry & Chemical Biology from Harvard University and received his B.A. from Dartmouth College.
Bill Young served as CEO of Monogram Biosciences, a leader in personalized medicine, from 1999 through to the sale of the company to LabCorp in 2009. Bill currently serves as chairman of the board of directors of Biogen IDEC, Inc., is a member of the board at Theravance, Inc, executive chairman of NanoString, and a venture partner at Clarus Ventures. Prior to Monogram he was at Genenetch since 1980 at positions of increasing responsibility, including chief operating officer responsible for all of the biotechnology company's development, operations and commercial functions. Prior to Genentech Mr. Young was at Eli Lilly and Company for fourteen years. Bill received his bachelor's degree in chemical engineering from Purdue University, his MBA from Indiana University and an honorary doctorate in engineering from Purdue University. In 1993 he was elected to the National Academy of Engineering for his leadership in research, development and manufacturing of recombinant proteins using recombinant DNA technology.
Ken Song, MD
Chief Executive Officer
Ken Song identified the core technology of Ariosa Diagnostics back in 2009 while he was a venture capitalist at Venrock. Ken served as Acting CEO of Ariosa in 2009 and assumed the CEO role. Prior to Ariosa, Ken was an investor at Venrock and led multiple investments in both public and private healthcare companies. Ken is a board certified physician, has extensive clinical and basic science research experience, and was previously a consultant at McKinsey & Company. Ken received his B.S. in Biology from the Massachusetts Institute of Technology and his M.D. from the University of California, San Francisco.